Small Molecules
5 February 2019
Idorsia announces the first patient recruited into REACT – the Phase 3 registration study with clazosentan4 February 2019
SK life science announces FDA acceptance of NDA submission for cenobamate, an investigational antiepileptic drug4 February 2019
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis4 February 2019
Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application1 February 2019
Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor in the United States1 February 2019
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator31 January 2019
Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute31 January 2019
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner31 January 2019
Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo29 January 2019
Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism29 January 2019
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis24 January 2019
Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia24 January 2019
X-Rx Announces FDA Acceptance of IND Application for X-165News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports